{"doi":"10.1002/9783527845088.ch13","title":"Molnupiravir","abstract":null,"journal":"Trends in Antiviral Drug Development","year":2025,"id":608484,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Molnupiravir","abstract":"Molnupiravir was the first orally bioavailable antiviral drug to receive conditional authorization for the treatment of COVID-19. When the bioactive form of molnupiravir, N 4 -hydroxycytidine-triphosphate (NHC-TP), is incorporated into the genomes of RNA viruses such as SARS-CoV-2, the compound can base-pair alternatively as cytidine or as uridine due to tautomeric conversions, resulting in the accumulation of randomly positioned mutations in the viral genomes with low allele frequency, which rapidly lead to collapse of the viral population. This mechanism of action has raised questions in three major areas that remain the topic of intense debate: Does the drug have host mutagenic potential? Can molnupiravir accelerate viral evolution? And does the therapeutic benefit of molnupiravir justify treatment? This review will discuss these questions based on the current experimental and clinical evidence.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W4409582014","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/9783527845088.ch13","host_type":"publisher"},{"url":"https://doi.org/10.1002/9783527845088.ch13","host_type":""}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","Respiratory viral infections research","Animal Virus Infections Studies"],"mesh_terms":[],"keywords":["Computer science"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T16:54:31.761862Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}